Innoviva is a Burlingame, California biopharmaceutical company that earns royalties on lung medicines and sells hospital critical care and antibiotic drugs. INVA reports earnings on Wed, Nov 4, 2026.
Prices, price targets and earnings estimates for INVA are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in INVA in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INVA is in one of them and how their past INVA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Innoviva
Innoviva is a biopharmaceutical company based in Burlingame, California. It earns royalties on inhaled medicines for asthma and chronic lung disease that GSK develops and sells. It also markets hospital medicines for critical care and serious bacterial infections, such as treatments for septic shock and pneumonia, which are used by hospitals and their patients. The company also holds stakes in other healthcare companies.
